The use of 5-aminosalicylate for patients with Crohn's disease in a prospective European inception cohort with 5 years follow-up - an Epi-IBD study
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
The use of 5-aminosalicylate for patients with Crohn's disease in a prospective European inception cohort with 5 years follow-up - an Epi-IBD study. / Burisch, Johan; Bergemalm, Daniel; Halfvarson, Jonas; Domislovic, Viktor; Krznaric, Zeljko; Goldis, Adrian; Dahlerup, Jens F; Oksanen, Pia; Collin, Pekka; de Castro, Luisa; Hernandez, Vicent; Turcan, Svetlana; Belousova, Elena; D'Incà, Renata; Sartini, Alessandro; Valpiani, Daniela; Giannotta, Martina; Misra, Ravi; Arebi, Naila; Duricova, Dana; Bortlik, Martin; Gatt, Kelly; Ellul, Pierre; Pedersen, Natalia; Kjeldsen, Jens; Andersen, Karina W; Andersen, Vibeke; Katsanos, Konstantinos H; Christodoulou, Dimitrios K; Sebastian, Shaji; Barros, Luisa; Magro, Fernando; Midjord, Jóngerð Mm; Nielsen, Kári R; Salupere, Riina; Kievit, Hendrika Al; Kiudelis, Gediminas; Kupčinskas, Juozas; Fumery, Mathurin; Gower-Rousseau, Corinne; Kaimakliotis, Ioannis P; Schwartz, Doron; Odes, Selwyn; Lakatos, Laszlo; Lakatos, Peter L; Langholz, Ebbe; Munkholm, Pia; Epi-IBD group.
I: United European Gastroenterology Journal, Bind 8, Nr. 8, 2020, s. 949-960.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - The use of 5-aminosalicylate for patients with Crohn's disease in a prospective European inception cohort with 5 years follow-up - an Epi-IBD study
AU - Burisch, Johan
AU - Bergemalm, Daniel
AU - Halfvarson, Jonas
AU - Domislovic, Viktor
AU - Krznaric, Zeljko
AU - Goldis, Adrian
AU - Dahlerup, Jens F
AU - Oksanen, Pia
AU - Collin, Pekka
AU - de Castro, Luisa
AU - Hernandez, Vicent
AU - Turcan, Svetlana
AU - Belousova, Elena
AU - D'Incà, Renata
AU - Sartini, Alessandro
AU - Valpiani, Daniela
AU - Giannotta, Martina
AU - Misra, Ravi
AU - Arebi, Naila
AU - Duricova, Dana
AU - Bortlik, Martin
AU - Gatt, Kelly
AU - Ellul, Pierre
AU - Pedersen, Natalia
AU - Kjeldsen, Jens
AU - Andersen, Karina W
AU - Andersen, Vibeke
AU - Katsanos, Konstantinos H
AU - Christodoulou, Dimitrios K
AU - Sebastian, Shaji
AU - Barros, Luisa
AU - Magro, Fernando
AU - Midjord, Jóngerð Mm
AU - Nielsen, Kári R
AU - Salupere, Riina
AU - Kievit, Hendrika Al
AU - Kiudelis, Gediminas
AU - Kupčinskas, Juozas
AU - Fumery, Mathurin
AU - Gower-Rousseau, Corinne
AU - Kaimakliotis, Ioannis P
AU - Schwartz, Doron
AU - Odes, Selwyn
AU - Lakatos, Laszlo
AU - Lakatos, Peter L
AU - Langholz, Ebbe
AU - Munkholm, Pia
AU - Epi-IBD group
PY - 2020
Y1 - 2020
N2 - BACKGROUND: The lack of scientific evidence regarding the effectiveness of 5-aminosalicylate in patients with Crohn's disease is in sharp contrast to its widespread use in clinical practice.AIMS: The aim of the study was to investigate the use of 5-aminosalicylate in patients with Crohn's disease as well as the disease course of a subgroup of patients who were treated with 5-aminosalicylate as maintenance monotherapy during the first year of disease.METHODS: In a European community-based inception cohort, 488 patients with Crohn's disease were followed from the time of their diagnosis. Information on clinical data, demographics, disease activity, medical therapy and rates of surgery, cancers and deaths was collected prospectively. Patient management was left to the discretion of the treating gastroenterologists.RESULTS: Overall, 292 (60%) patients with Crohn's disease received 5-aminosalicylate period during follow-up for a median duration of 28 months (interquartile range 6-60). Of these, 78 (16%) patients received 5-aminosalicylate monotherapy during the first year following diagnosis. Patients who received monotherapy with 5-aminosalicylate experienced a mild disease course with only nine (12%) who required hospitalization, surgery, or developed stricturing or penetrating disease, and most never needed more intensive therapy. The remaining 214 patients were treated with 5-aminosalicylate as the first maintenance drug although most eventually needed to step up to other treatments including immunomodulators (75 (35%)), biological therapy (49 (23%)) or surgery (38 (18%)).CONCLUSION: In this European community-based inception cohort of unselected Crohn's disease patients, 5-aminosalicylate was commonly used. A substantial group of these patients experienced a quiescent disease course without need of additional treatment during follow-up. Therefore, despite the controversy regarding the efficacy of 5-aminosalicylate in Crohn's disease, its use seems to result in a satisfying disease course for both patients and physicians.
AB - BACKGROUND: The lack of scientific evidence regarding the effectiveness of 5-aminosalicylate in patients with Crohn's disease is in sharp contrast to its widespread use in clinical practice.AIMS: The aim of the study was to investigate the use of 5-aminosalicylate in patients with Crohn's disease as well as the disease course of a subgroup of patients who were treated with 5-aminosalicylate as maintenance monotherapy during the first year of disease.METHODS: In a European community-based inception cohort, 488 patients with Crohn's disease were followed from the time of their diagnosis. Information on clinical data, demographics, disease activity, medical therapy and rates of surgery, cancers and deaths was collected prospectively. Patient management was left to the discretion of the treating gastroenterologists.RESULTS: Overall, 292 (60%) patients with Crohn's disease received 5-aminosalicylate period during follow-up for a median duration of 28 months (interquartile range 6-60). Of these, 78 (16%) patients received 5-aminosalicylate monotherapy during the first year following diagnosis. Patients who received monotherapy with 5-aminosalicylate experienced a mild disease course with only nine (12%) who required hospitalization, surgery, or developed stricturing or penetrating disease, and most never needed more intensive therapy. The remaining 214 patients were treated with 5-aminosalicylate as the first maintenance drug although most eventually needed to step up to other treatments including immunomodulators (75 (35%)), biological therapy (49 (23%)) or surgery (38 (18%)).CONCLUSION: In this European community-based inception cohort of unselected Crohn's disease patients, 5-aminosalicylate was commonly used. A substantial group of these patients experienced a quiescent disease course without need of additional treatment during follow-up. Therefore, despite the controversy regarding the efficacy of 5-aminosalicylate in Crohn's disease, its use seems to result in a satisfying disease course for both patients and physicians.
U2 - 10.1177/2050640620945949
DO - 10.1177/2050640620945949
M3 - Journal article
C2 - 32715989
VL - 8
SP - 949
EP - 960
JO - United European Gastroenterology Journal
JF - United European Gastroenterology Journal
SN - 2050-6406
IS - 8
ER -
ID: 258828534